Effects of anti TNF α antibody (infliximab) plus MTX on SCID-HuRAg-pit model

2006 Fiscal Year Final Research Report Summary

• Project/Area Number: 17591600
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: Toin University of Yokohama
• Principal Investigator: OCHIAI Akira Toin University of Yokohama, Faculty of Biomedical Engineering, Associate Professor, 医用工学部臨床工学科, 准教授 (60398972)
• Co-Investigator(Kenkyū-buntansha): GOTO Makoto Toin University of Yokohama, Faculty of Biomedical Engineering, Professor, 医用工学部臨床工学科, 教授 (00170465)
• Project Period (FY): 2005 – 2006
• Keywords: Rheumatoid Arthritis / osteoclast / anti-TNF antibody

Research Abstract

We already developed SCID-HuRAg-pit model which is dentin slice are engrafted with rheumatoid arthritis (RA) synovial tissues on back of SCID mice.
In this study, we investigate effects of infliximab alone or infliximab plus methotrexate (MTX) for SCID-HuRAg-pit model. Administration of infliximab was using by osmotic pump. Methotrexate was administered orally 3 times per week. Control group was administrated human IgG. The engrafted synovial tissues were taken 4 weeks after transplantation and measured pit-formation. Moreover, plasma TNF-a, IL-6 were also measured. Plasma TNF-a and IL-6 concentrations were decreased in the group of infliximab administrated. However, there is no significant finding on the number of pit-formation on dentin. On the other hand, in case of infliximab plus MTX were significant differences about the number of pit-formation on dentin. These results suggest that the anti TNF-α antibody and MTX combination was useful against inhibition of bone destruction.